Clinical Trials Browser

Interventional × Ascites × catumaxomab × Clear all

NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms